[ad_1]
At the Szeged University (SZTE) clinic, coronavirus patients will be treated for the first time in the country with the Avigan drug containing favipiravir, which is expected to have a shorter recovery time and fewer complications.
In a statement from SZTE, Csaba Lengyel, president of SZTE’s Albert Szent-Györgyi Clinical Center, reported that the university was the first in the country to start using the drug, which has been encouraging in Japan so far.
A clinical trial of the broad-spectrum Japanese antiviral drug, favipiravir, was initiated in the HECRIN consortium. The consortium is also a member of the SZTE Clinical Trials Coordination Office, which was involved in preparing the trials in Hungary. This is how the University of Szeged received the most promising drug, which was previously donated by the Japanese government to 44 countries, including Hungary.
In a clinical trial in Japan over the past six months, favipiravir prevented the proliferation of viral RNA in the body in moderate coronavirus patients with incipient pneumonia and alleviated clinical symptoms such as fever or respiratory distress within 12 days. It has also successfully prevented the deterioration of patients.
Based on a medical decision, the drug should only be administered to critically ill patients in a hospital according to the study criteria.
At the same time, development of a drug containing favipiravir is underway in Hungary, so experts hope that clinical testing of it will start soon – read the announcement.
[ad_2]
